entX
An innovation hub specializing in nuclear science and engineering to develop long-term power systems, life-saving medical isotopes, and clean energy technologies for space, defense, and healthcare.
- CEO / Founder
- Bryn Jones
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $30.2M
- Latest Round
- Grant
- Key Investors
- Foxglove Capital, Australian Government (Department of Industry, Science and Resources), South Australian Government (Economic Recovery Fund)
Technology & Products
Key Products
Nuclear batteries (betavoltaic devices) for space and defense, medical isotopes for cancer treatments, and clean energy technologies (green hydrogen and ammonia).
Technological Advantage
Utilizes proprietary semiconductor deposition and additive manufacturing (3D printing) to integrate radioactive layers into compact frames, significantly increasing energy density compared to traditional methods. Also features the ability to recover valuable isotopes from unconventional sources like mine tailings and waste streams.
Differentiation
Value Proposition
Provides maintenance-free, self-sustaining power for decades in extreme environments and establishes a sovereign, reliable supply chain for critical cancer-fighting isotopes.
How They Differentiate
Proprietary use of additive manufacturing (3D printing) to integrate radioactive layers directly into compact structural frames, enabling higher energy density and durability compared to traditional semiconductor deposition.
Market & Competition
Target Customers
Space agencies (e.g., ASA, NASA), defense contractors, global radiopharmaceutical companies, and heavy industrial firms seeking decarbonization solutions.
Industry Verticals
["Space & Aerospace","Defense","Healthcare (Nuclear Medicine)","Clean Energy","Heavy Industry & Mining"]
Competitors
City Labs; Arkenlight; SHINE Technologies; Betavolt
Growth & Milestones
Growth Metrics
Secured $19.1M+ in government grants alongside $27M in private capital; targeting flight heritage missions for 2026-2027.
Major Milestones
["Rebranded from PhosEnergy to entX in 2023 to reflect a broader nuclear and clean energy focus.","Awarded $2.915M CRC-P Grant in October 2024 for the IsoMedica medical isotope facility.","Collaborated with the University of Adelaide in February 2026 to scale GenX nuclear battery production via additive manufacturing."]
Notable Customers
Australian Space Agency (ASA); Australian Department of Defence; University of Adelaide; ANSTO